Neurotech International Ltd. (AU:NTI) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Neurotech International Ltd, a clinical-stage biopharmaceutical company specializing in pediatric neurological disorders, successfully held its Annual General Meeting, with all resolutions carried. The company, known for its NTI164 cannabinoid drug therapy, has shown significant promise in trials for Autism Spectrum Disorder and other neurological conditions. Investors might find potential growth opportunities as Neurotech advances its clinical trials in spastic cerebral palsy.
For further insights into AU:NTI stock, check out TipRanks’ Stock Analysis page.